P-1502. Clindamycin and Group A Streptococcus: Is It Time To Say Goodbye?

dc.contributor.authorMann, Keeret
dc.contributor.authorZijoo, Ritika
dc.contributor.authorLugar, Richard G.
dc.contributor.departmentGraduate Medical Education, School of Medicine
dc.date.accessioned2025-02-25T12:57:34Z
dc.date.available2025-02-25T12:57:34Z
dc.date.issued2025-01-29
dc.description.abstractBackground: Group A streptococci (GAS) can cause invasive disease leading to Toxic Shock Syndrome (TSS), a condition linked with high mortality. Initial antibiotic therapy for GAS-TSS includes beta-lactams and clindamycin. When clindamycin resistance is noted, linezolid may be used instead until clinical stability is achieved. We reviewed GAS susceptibility at IUH Ball Memorial Hospital to assess appropriateness of initial clindamycin use as adjunctive therapy for GAS-TSS. Methods: GAS positive cultures recovered from 1/1/23 – 12/31/23 at IU Health Ball Memorial Hospital, Muncie, IN were reviewed. Results: Out of 162 cultures positive for GAS, 29 (17.9%) had susceptibility results. All 29 GAS specimens were sensitive to penicillin and linezolid, but only 16/29 (55.2%) specimens were sensitive to clindamycin. Table 1. and Chart 1. show susceptibility results for penicillin, clindamycin, erythromycin, and linezolid. Table 2. shows number of specimens with inducible clindamycin resistance. Chart 2. shows various sources of culture specimens. Conclusion: GAS susceptibility testing was performed with invasive infections or when requested. Significant resistance was noted to clindamycin. Although our data is limited by a small sample size, it is in line with trends noted by US CDC’s Active Bacterial Core surveillance reports. This raises concern over initial use of clindamycin for TSS before susceptibilities are available. There are both advantages and disadvantages associated with use of clindamycin or linezolid. There is more data to support clindamycin use, however it is linked with increased risk of C. difficile infections. There is limited data for the use of linezolid for this indication, but it does maintain better susceptibility and negates the use of vancomycin at time of empiric therapy. Even though more data may be needed to definitively recommend linezolid over clindamycin or vice versa, clinical decisions will need to be made prior to susceptibility results. We recommend clinicians utilize their local antibiograms to guide decision making, while also accounting for patient factors. This also provides an opportunity for the development of clinical practice guidelines to better assist clinicians in the community.
dc.eprint.versionFinal published version
dc.identifier.citationMann K, Zijoo R, Lugar RG. P-1502. Clindamycin and Group A Streptococcus: Is It Time To Say Goodbye?. Open Forum Infect Dis. 2025;12(Suppl 1):ofae631.1671. Published 2025 Jan 29. doi:10.1093/ofid/ofae631.1671
dc.identifier.urihttps://hdl.handle.net/1805/46013
dc.language.isoen_US
dc.publisherOxford University Press
dc.relation.isversionof10.1093/ofid/ofae631.1671
dc.relation.journalOpen Forum Infectious Diseases
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.sourcePMC
dc.subjectGroup A streptococci (GAS)
dc.subjectToxic Shock Syndrome (TSS)
dc.subjectAntibiotic therapy
dc.subjectBeta-lactams
dc.subjectClindamycin
dc.titleP-1502. Clindamycin and Group A Streptococcus: Is It Time To Say Goodbye?
dc.typeAbstract
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Mann2025Clindamycin-CCBY.pdf
Size:
169.14 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: